A Phase 3 interventional study of Atogepant and Placebo for Atogepant in Migraine, sponsored by AbbVie. Completed at 48 sites in Japan. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing atogepant in Migraine Disorders — 6 open to participants now, 7 under way, 4 of them phase 3. atogepant · Migraine Disorders.
Among the 21 studies testing atogepant in Migraine Disorders, this one is the 10th largest by enrollment, is one of 3 that started in 2023, is one of 15 in phase 3, and was the 15th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →6 of the 21 studies testing atogepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–70
AbbVie · Sites in United States, Canada, Denmark and 8 more countries
Ages 12–17
AbbVie · Sites in United States, Belgium, Canada and 13 more countries
Ages 6–17
AbbVie · Sites in United States, Belgium, Canada and 13 more countries
Ages 6–17
Konrad Peter Weber · Sites in Switzerland
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
atogepant: first FDA approval 2021 (QULIPTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 16 · Phase 4 4
First in 2016; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 524 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 468 across the 21 interventional studies. Of the 14 that completed or were terminated, 11 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 21 have an industry lead sponsor. The 5 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
55 studies in Migraine Disorders by AbbVie: 9 open now, 13 under way, 7 of them phase 3. Of 40 finished, 32 (80%) have results posted.
Among the 55 studies in Migraine Disorders by AbbVie, this one is the 21st largest by enrollment of the 41 interventional ones that give a count, is one of 6 that started in 2023, is one of 30 in phase 3, and was the 45th registered.
AbbVie’s Migraine Disorders studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing atogepant in Migraine Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 55 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. This study will assess how safe and effective three different doses of atogepant is compared to placebo in adult Japanese participants. Change in migraine symptoms will be assessed.
Atogepant (Qulipta) is an approved drug to treat adults with episodic migraine in the United States. Participants are randomly assigned to one of the 4 treatment groups called Arms to receive atogepant or matching placebo. There is 1 in a 4 chance for the participant to receive placebo. This is double-blinded study which means neither study doctor not the participant will know if the participant received atogepant or placebo. Approximately 520 adult participants with episodic migraine will be enrolled in approximately 50 sites across Japan.
Participants will receive oral atogepant or matching placebo tablets once daily for 12 weeks. At 12 weeks participants assigned to atogepant dose A, dose B or dose C will continue to receive same treatment for 12 additional weeks and participants assigned to placebo will be re-randomized to receive atogepant dose A, dose B or dose C for 12 additional weeks. All participants will be followed for 30 days following last dose of study drug.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The safety and tolerability of the treatment will be checked by medical assessments, blood tests, checking for adverse events and completing questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive atogepant dose A once daily (QD) for 24 weeks.
Drug: Atogepant
Participants will receive atogepant dose B QD for 24 weeks.
Drug: Atogepant
Participants will receive atogepant dose C QD for 24 weeks.
Drug: Atogepant
Participants will receive placebo QD for 12 weeks. Participants will be re-randomized at week 12 to receive atogepant dose A, dose B or dose C QD for 12 weeks.
Drug: Atogepant · Drug: Placebo for Atogepant
Oral Tablet
Also known as: Qulipta
Oral Tablet
Change From Baseline in Mean Monthly Migraine Days
Participants recorded daily duration of migraine in an eDiary. A migraine day was any calendar day on which the participant experienced a migraine headache qualified by duration or acute symptomatic medication use. The monthly (4-week) migraine days was defined as the total number of reported migraine days in eDiary divided by total number of days with eDiary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline was defined as the number of migraine days during the last 28 days of the Baseline phase, from Day -28 to -1. Negative change from Baseline indicates improvement. A Mixed-effects Model for Repeated Measure (MMRM) was used for analysis.
Time frame: Up to Week 12
Number of Participants Experiencing With Adverse Events (AEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Up to Week 12
Change From Baseline in Mean Monthly Headache Days
Participants recorded daily total duration of a headache in an eDiary. A headache day is any calendar day on which the participant experienced a headache qualified by duration or acute symptomatic medication use. The monthly (4-week) headache days were defined as the total number of reported headache days in the eDiary divided by the total number of days with eDiary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline was defined as the number of migraine days during the last 28 days of the Baseline phase, from Day -28 to -1. Negative change from Baseline indicates improvement. MMRM was used for analysis.
Time frame: Up to Week 12
Change From Baseline in Mean Monthly Acute Medication Use Days
Participants recorded allowed medication(s) to treat an acute migraine in the daily eDiary. The monthly (4-week) acute medication use days was defined as the total number of reported acute medication use days in the eDiary divided by the total number of days with eDiary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline was defined as the number of acute medication use days during the last 28 days of the Baseline phase, from Day -28 to -1. A negative change from Baseline indicates improvement. MMRM was used for the analysis.
Time frame: Up to Week 12
Percentage of Participants Achieving At Least 50% Reduction in the 3-month Average of Monthly Migraine Days
Participants recorded daily duration of migraine in an eDiary. A migraine day was any calendar day on which the participant experienced a migraine headache qualified by duration or acute symptomatic medication use. The monthly (4-week) migraine days is equal to total number of reported migraine days in eDiary divided by total number of days with eDiary records in each 4-week period multiplied by 28. Each 4-week period was averaged.
Time frame: Up to Week 12
Change From Baseline in Migraine Specific Quality of Life Questionnaire, Version 2.1 (MSQ v2.1) Role Function-Restrictive Domain Score
MSQ v2.1 is a 14-item questionnaire designed to measure health-related quality-of-life impairments attributed to migraine in the past 4 weeks. It is divided into three domains: role function-restrictive (questions 1-7, score range 7 to 42) assesses how migraines limit one's daily social and work-related activities; role function-preventive (questions 8-11, score ranges 4 to 24) assesses how migraines prevent these activities; and the emotional function (questions 12-14, score ranges 3 to 18) domain assesses the emotions associated with migraines. Participants respond to items using a 6-point scale where 1=none of the time and 6=all of the time. Raw dimension scores are computed as a sum of item responses and rescaled to a 0 to 100 scale, where higher scores from Baseline indicate better quality of life. MMRM was used for the analysis.
Time frame: Up to Week 12
Change From Baseline in Mean Monthly Performance of Daily Activities Domain Score of the Activity Impairment in Migraine - Diary (AIM-D)
The AIM-D is an 11-item daily diary measure that assesses the impact of migraine and is comprised of two domains that evaluate performance of daily activities (7 items) and physical impairment (4 items). Participants are asked to rate the level of difficulty experienced in the past 24 hours with performance of daily activities and physical impairment using a 6 point rating scale ranging from "Not difficult at all" to "I could not do it at all." Scores range from 0-100 scale, with higher scores indicating greater impact of migraine.
Time frame: Up to Week 12
Change From Baseline in Mean Monthly Physical Impairment Domain Score of the AIM-D
The AIM-D is an 11-item daily diary measure that assesses the impact of migraine and is comprised of two domains that evaluate performance of daily activities (7 items) and physical impairment (4 items). Participants are asked to rate the level of difficulty experienced in the past 24 hours with performance of daily activities and physical impairment using a 6 point rating scale ranging from "Not difficult at all" to "I could not do it at all." Scores range from 0-100 scale, with higher scores indicating greater impact of migraine.
Time frame: Up to Week 12
| Milestone | Placebo | Placebo/Atogepant 10 mg | Placebo/Atogepant 30 mg | Placebo/Atogepant 60 mg | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg |
|---|---|---|---|---|---|---|---|
| Started | 134 | 0 | 0 | 0 | 127 | 131 | 132 |
| Never received any study treatment | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Received randomized study treatment | 133 | 0 | 0 | 0 | 126 | 131 | 131 |
| Received study treatment other than randomized | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Completed | 131 | 0 | 0 | 0 | 124 | 126 | 130 |
| Not completed | 3 | 0 | 0 | 0 | 3 | 5 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 1 | 2 | 1 |
| Withdrew: Not disclosed | 1 | 0 | 0 | 0 | 2 | 3 | 1 |
| Milestone | Placebo | Placebo/Atogepant 10 mg | Placebo/Atogepant 30 mg | Placebo/Atogepant 60 mg | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg |
|---|---|---|---|---|---|---|---|
| Started | 0 | 46 | 43 | 42 | 124 | 126 | 130 |
| Completed | 0 | 45 | 43 | 41 | 121 | 125 | 126 |
| Not completed | 0 | 1 | 0 | 1 | 3 | 1 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 2 | 0 | 2 |
| Withdrew: Not disclosed | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
Participants recorded daily duration of migraine in an eDiary. A migraine day was any calendar day on which the participant experienced a migraine headache qualified by duration or acute symptomatic medication use. The monthly (4-week) migraine days was defined as the total number of reported migraine days in eDiary divided by total number of days with eDiary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline was defined as the number of migraine days during the last 28 days of the Baseline phase, from Day -28 to -1. Negative change from Baseline indicates improvement. A Mixed-effects Model for Repeated Measure (MMRM) was used for analysis.
| migraine days per month | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg |
|---|---|---|---|---|
| Change From Baseline in Mean Monthly Migraine Days | -1.24 (-1.72 to -0.75) | -2.80 (-3.30 to -2.30) | -3.14 (-3.63 to -2.64) | -3.34 (-3.83 to -2.85) |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
| Participants | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg |
|---|---|---|---|---|
| Number of Participants Experiencing With Adverse Events (AEs) | 62 | 57 | 51 | 57 |
Participants recorded daily total duration of a headache in an eDiary. A headache day is any calendar day on which the participant experienced a headache qualified by duration or acute symptomatic medication use. The monthly (4-week) headache days were defined as the total number of reported headache days in the eDiary divided by the total number of days with eDiary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline was defined as the number of migraine days during the last 28 days of the Baseline phase, from Day -28 to -1. Negative change from Baseline indicates improvement. MMRM was used for analysis.
| headache days per month | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg |
|---|---|---|---|---|
| Change From Baseline in Mean Monthly Headache Days | -1.01 ± 0.269 | -3.17 ± 0.277 | -3.31 ± 0.274 | -3.50 ± 0.275 |
Participants recorded allowed medication(s) to treat an acute migraine in the daily eDiary. The monthly (4-week) acute medication use days was defined as the total number of reported acute medication use days in the eDiary divided by the total number of days with eDiary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline was defined as the number of acute medication use days during the last 28 days of the Baseline phase, from Day -28 to -1. A negative change from Baseline indicates improvement. MMRM was used for the analysis.
| acute medication use days per month | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg |
|---|---|---|---|---|
| Change From Baseline in Mean Monthly Acute Medication Use Days | -0.22 ± 0.246 | -2.34 ± 0.254 | -2.55 ± 0.250 | -2.69 ± 0.250 |
Participants recorded daily duration of migraine in an eDiary. A migraine day was any calendar day on which the participant experienced a migraine headache qualified by duration or acute symptomatic medication use. The monthly (4-week) migraine days is equal to total number of reported migraine days in eDiary divided by total number of days with eDiary records in each 4-week period multiplied by 28. Each 4-week period was averaged.
| percentage of participants | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving At Least 50% Reduction in the 3-month Average of Monthly Migraine Days | 15.0 | 40.9 | 42.3 | 50.4 |
MSQ v2.1 is a 14-item questionnaire designed to measure health-related quality-of-life impairments attributed to migraine in the past 4 weeks. It is divided into three domains: role function-restrictive (questions 1-7, score range 7 to 42) assesses how migraines limit one's daily social and work-related activities; role function-preventive (questions 8-11, score ranges 4 to 24) assesses how migraines prevent these activities; and the emotional function (questions 12-14, score ranges 3 to 18) domain assesses the emotions associated with migraines. Participants respond to items using a 6-point scale where 1=none of the time and 6=all of the time. Raw dimension scores are computed as a sum of item responses and rescaled to a 0 to 100 scale, where higher scores from Baseline indicate better quality of life. MMRM was used for the analysis.
| score on a scale | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg |
|---|---|---|---|---|
| Change From Baseline in Migraine Specific Quality of Life Questionnaire, Version 2.1 (MSQ v2.1) Role Function-Restrictive Domain Score | 8.33 ± 1.229 | 15.39 ± 1.265 | 17.19 ± 1.250 | 17.55 ± 1.245 |
The AIM-D is an 11-item daily diary measure that assesses the impact of migraine and is comprised of two domains that evaluate performance of daily activities (7 items) and physical impairment (4 items). Participants are asked to rate the level of difficulty experienced in the past 24 hours with performance of daily activities and physical impairment using a 6 point rating scale ranging from "Not difficult at all" to "I could not do it at all." Scores range from 0-100 scale, with higher scores indicating greater impact of migraine.
| score on a scale | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg |
|---|---|---|---|---|
| Change From Baseline in Mean Monthly Performance of Daily Activities Domain Score of the Activity Impairment in Migraine - Diary (AIM-D) | -2.35 ± 0.357 | -4.73 ± 0.369 | -5.31 ± 0.364 | -4.90 ± 0.367 |
The AIM-D is an 11-item daily diary measure that assesses the impact of migraine and is comprised of two domains that evaluate performance of daily activities (7 items) and physical impairment (4 items). Participants are asked to rate the level of difficulty experienced in the past 24 hours with performance of daily activities and physical impairment using a 6 point rating scale ranging from "Not difficult at all" to "I could not do it at all." Scores range from 0-100 scale, with higher scores indicating greater impact of migraine.
| score on a scale | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg |
|---|---|---|---|---|
| Change From Baseline in Mean Monthly Physical Impairment Domain Score of the AIM-D | -2.12 ± 0.351 | -4.32 ± 0.363 | -4.89 ± 0.357 | -4.49 ± 0.360 |
Collected over All-cause mortality & AE tables include events reported from time of informed consent to end of study. Median time on follow-up was 200, 200.5, 200, 200, 200, 201 & 200 days for Pbo, Pbo/10mg, Pbo/30mg, Pbo/60mg, Atogepant 10mg, 30mg & 60mg, respectively. One subject randomized to 60mg never recd study treatment (included in ITT 60mg but not in SP1); one subject randomized to 10mg took 60mg; one subject randomized to placebo then re-randomized to 60mg at Wk 12 recd 30mg from Wk 12-24.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/134 (0%) | 1/134 (0.7%) | 38/134 (28.4%) |
| Placebo/Atogepant 10 mg | 0/46 (0%) | 1/46 (2.2%) | 18/46 (39.1%) |
| Placebo/Atogepant 30 mg | 0/43 (0%) | 0/44 (0%) | 15/44 (34.1%) |
| Placebo/Atogepant 60 mg | 0/42 (0%) | 0/41 (0%) | 12/41 (29.3%) |
| Atogepant 10 mg | 0/127 (0%) | 2/126 (1.6%) | 39/126 (31%) |
| Atogepant 30 mg | 0/131 (0%) | 1/131 (0.8%) | 40/131 (30.5%) |
| Atogepant 60 mg | 0/132 (0%) | 0/132 (0%) | 40/132 (30.3%) |
| Event | Placebo | Placebo/Atogepant 10 mg | Placebo/Atogepant 30 mg | Placebo/Atogepant 60 mg | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg |
|---|---|---|---|---|---|---|---|
| HAEMORRHOIDSGastrointestinal disorders | 1/134 | 1/46 | 0/44 | 0/41 | 0/126 | 0/131 | 0/132 |
| PRINZMETAL ANGINACardiac disorders | 0/134 | 0/46 | 0/44 | 0/41 | 1/126 | 0/131 | 0/132 |
| OROPHARYNGEAL CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/134 | 0/46 | 0/44 | 0/41 | 1/126 | 0/131 | 0/132 |
| ANAEMIABlood and lymphatic system disorders | 0/134 | 0/46 | 0/44 | 0/41 | 0/126 | 1/131 | 0/132 |
| Event | Placebo | Placebo/Atogepant 10 mg | Placebo/Atogepant 30 mg | Placebo/Atogepant 60 mg | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg |
|---|---|---|---|---|---|---|---|
| NASOPHARYNGITISInfections and infestations | 27/134 | 7/46 | 11/44 | 9/41 | 21/126 | 23/131 | 19/132 |
| CONSTIPATIONGastrointestinal disorders | 12/134 | 7/46 | 2/44 | 3/41 | 6/126 | 13/131 | 15/132 |
| COVID-19Infections and infestations | 5/134 | 2/46 | 3/44 | 0/41 | 9/126 | 4/131 | 7/132 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 0/134 | 3/46 | 0/44 | 1/41 | 3/126 | 5/131 | 5/132 |
| PYREXIAGeneral disorders | 0/134 | 2/46 | 1/44 | 1/41 | 4/126 | 0/131 | 2/132 |
| GASTRITISGastrointestinal disorders | 0/134 | 1/46 | 0/44 | 1/41 | 1/126 | 1/131 | 1/132 |
| VAGINAL HAEMORRHAGEReproductive system and breast disorders | 0/134 | 0/46 | 0/44 | 0/41 | 0/126 | 0/131 | 0/132 |
Safety Population 1; One participant was randomized but never received any study treatment.
| Age, Continuous(years) | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg | Total |
|---|---|---|---|---|---|
| Mean | 44.8 ± 10.54 | 41.3 ± 11.71 | 43.2 ± 11.40 | 42.5 ± 10.25 | 43.0 ± 11.02 |
| Sex: Female, Male(Participants) | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg | Total |
|---|---|---|---|---|---|
| Female | 117 | 106 | 104 | 110 | 437 |
| Male | 17 | 20 | 27 | 22 | 86 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 134 | 126 | 131 | 132 | 523 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Atogepant 10 mg | Atogepant 30 mg | Atogepant 60 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 134 | 126 | 131 | 132 | 523 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Jul 2023 to primary completion in Mar 2025, 19 months.
Results were first posted in Jun 2026, 1 year 3 months after primary completion.
Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 19 months is close to that.
Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atogepant